Loading
A phase 2/3 trial testing Cobolimab in non-small-cell lung cancer, active and no longer recruiting.
Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy is a phase 2/3 interventional study registered as NCT04655976, led by GlaxoSmithKline, and active but no longer recruiting on the registry. Official title: A Randomised, Open Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab + Docetaxel To Dostarlimab + Docetaxel To Docetaxel Alone In Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed On Prior Anti-PD-(L)1 Therapy And Chemotherapy (COSTAR Lung). Planned enrolment is 758 participants (actual). The study started in 2020-12-08 and primary completion is expected in 2025-06-05. Results have been posted on ClinicalTrials.gov; they are not yet summarised here.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
758 enrolled.
95% CI 10.6 to 14.2; Figures from the ClinicalTrials.gov results section (first posted 2026-07-01), not from a publication · 95% CI 9.5 to 13.9
Source95% CI 10.3 to 12.9; Figures from the ClinicalTrials.gov results section (first posted 2026-07-01), not from a publication · 95% CI 9.5 to 13.9
Source95% CI 4.2 to 5.5; Figures from the ClinicalTrials.gov results section (first posted 2026-07-01), not from a publication · 95% CI 4.0 to 5.4 · 95% CI 2.9 to 4.8
Source95% CI 14.5 to 23.5; Figures from the ClinicalTrials.gov results section (first posted 2026-07-01), not from a publication · 95% CI 14.1 to 23.1 · 95% CI 9.3 to 21.1
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall Survival (OS) (Arm A Versus Arm C)primary | Cobolimab + Dostarlimab + Docetaxel (Arm A) | 305 | 11.9 months | 0.85 (0.68 to 1.06) | 0.079708 | link |
| Docetaxel (Arm C) | 152 | 11.3 months | ||||
| Overall Survival (OS) (Arm B Versus Arm C)primary | Dostarlimab + Docetaxel (Arm B) | 301 | 11.8 months | 0.96 (0.77 to 1.2) | 0.369509 | link |
| Docetaxel (Arm C) | 152 | 11.3 months | ||||
| Progression Free Survival (PFS) | Cobolimab + Dostarlimab + Docetaxel (Arm A) | 305 | 4.4 months | - | - | link |
| Dostarlimab + Docetaxel (Arm B) | 301 | 4.2 months | ||||
| Docetaxel (Arm C) | 152 | 4.1 months | ||||
| Overall Response Rate (ORR) | Cobolimab + Dostarlimab + Docetaxel (Arm A) | 305 | 18.7% | - | - | link |
| Dostarlimab + Docetaxel (Arm B) | 301 | 18.3% | ||||
| Docetaxel (Arm C) | 152 | 14.5% |
Shares TIM-3 blockade, Cobolimab, GSK.
Shares TIM-3 blockade, Cobolimab.
Shares GSK, Non-small-cell lung cancer.
Shares GSK, Non-small-cell lung cancer.
Shares TIM-3 blockade, Non-small-cell lung cancer.